Clinical Trials
64 trialsAzacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
National Cancer Institute (NCI)
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
National Cancer Institute (NCI)
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
National Cancer Institute (NCI)
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
National Cancer Institute (NCI)
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
National Cancer Institute (NCI)
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
National Cancer Institute (NCI)
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
National Institutes of Health Clinical Center (CC)
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Kidney Cancer
National Cancer Institute (NCI)
TARGET
National Cancer Institute (NCI)
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
National Cancer Institute (NCI)
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)